{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:10:33Z","timestamp":1789139433592,"version":"build-2803163510"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["I01BX007265"],"award-info":[{"award-number":["I01BX007265"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["P30EY001792"],"award-info":[{"award-number":["P30EY001792"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R24EY032440"],"award-info":[{"award-number":["R24EY032440"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Richard A. Perritt M.D. Charitable Foundation"},{"name":"Dr. John P. and Therese E. Mulcahy Endowed Professorship in Ophthalmology"},{"DOI":"10.13039\/100017982","name":"Illinois Society for the Prevention of Blindness","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017982","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Antibody\u2013drug conjugate (ADC)-associated ocular toxicity is an emerging, sometimes dose-limiting complication. Macropinocytosis has been implicated in off-target ADC uptake by corneal epithelial cells. This study evaluated whether ocular surface immunoglobulin (OSIG) inhibit macropinocytosis in human corneal epithelial cells (HCE-T) and characterized ocular biodistribution and tolerability following topical and subconjunctival administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Macropinocytosis was quantified in corneal epithelial cells after exposure to vehicle or increasing concentrations of OSIG. Ocular pharmacokinetics were evaluated in New Zealand White rabbits following single topical instillation or subconjunctival injection of 5% OSIG. OSIG concentrations were quantified in ocular tissues, ocular fluids, tears, serum, and submandibular lymph nodes using enzyme-linked immunosorbent assay (ELISA). Local tolerability was assessed after single and repeated subconjunctival injections using clinical observations, Draize scoring, and ophthalmic examinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>OSIG inhibited Dextran Texas Red uptake in a concentration-dependent manner, with near-complete inhibition at 5%. Topical OSIG produced only transient conjunctival exposure and did not achieve sustained corneal concentrations. In contrast, subconjunctival administration resulted in sustained ocular surface exposure, with peak corneal concentration of 11,200.8 ng\/g on Day 14 and measurable conjunctival exposure through 28 days. Serum exposure was detectable but lower than ocular surface tissue exposure. Subconjunctival OSIG was generally well tolerated after single and repeated dosing, with findings limited mainly to transient conjunctival redness and chemosis. Two clinical cases of ADC-associated ocular toxicity treated with topical OSIG were also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>OSIG inhibits macropinocytosis in HCE-T and achieves sustained corneal and conjunctival exposure following subconjunctival administration. These findings support further evaluation of subconjunctival OSIG as a local strategy to mitigate ADC-associated corneal toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261475776","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:46:39Z","timestamp":1786081599000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ocular Tissue Distribution of Ocular Surface Immunoglobulin\u00a0Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of Antibody\u2013Drug Conjugate-Associated Ocular Toxicity"],"prefix":"10.1177","author":[{"given":"Zeenal","family":"Dabre","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"Krupa","sequence":"additional","affiliation":[{"name":"Program in Molecular Pharmacology and Therapeutics, Loyola University Chicago, Health Sciences Campus, Maywood, Maywood, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvanachandra","family":"Pasupuleti","sequence":"additional","affiliation":[{"name":"Research and Development, Selagine, Inc., Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Bacellar-Galdino","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Loyola University Chicago, Health Sciences Campus, Maywood, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee D.","family":"Troughton","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Loyola University Chicago, Health Sciences Campus, Maywood, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Research and Development, Selagine, Inc., Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Geun","family":"Moon","sequence":"additional","affiliation":[{"name":"Research and Development, Selagine, Inc., Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Flavin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6878-521X","authenticated-orcid":false,"given":"Simon","family":"Kaja","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Loyola University Chicago, Health Sciences Campus, Maywood, Illinois, USA."},{"name":"Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Health Sciences Campus, Maywood, Illinois, USA."},{"name":"Department of Microbiology and Immunology, Loyola University Chicago, Health Sciences Campus, Maywood, Illinois, USA."},{"name":"Research Service, Edward Hines Jr. VA Hospital, Hines, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01704-3"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules31030419"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105573"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00285"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00987"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.04.016"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.12.036"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03649-z"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01720-3"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101302"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.10.003"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.008"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2024.0019"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0710"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3202"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.10.004"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2024.2381207"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_608_25"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(00)00210-1"},{"issue":"3","key":"e_1_3_2_27_1","first-page":"614","article-title":"An SV40-immortalized human corneal epithelial cell line and its characterization","volume":"36","author":"Araki-Sasaki K","year":"1995","unstructured":"26.Araki-Sasaki K, , Ohashi Y, , Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci 1995;36(3):614\u2013621.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091362"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1465776"},{"key":"e_1_3_2_30_1","unstructured":"29.Teich E Krupa E Troughton LD et al. Efficacy of ocular surface immune globulins in models for dry eye disease | IOVS | ARVO Journals. Available from: https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2816140 [Last accessed: 19July 2026]."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0108"},{"key":"e_1_3_2_32_1","unstructured":"31.Ocular pharmacokinetic and safety studies | Springer Nature Link. Available from: https:\/\/link.springer.com\/rwe\/10.1007\/978-3-030-73317-9_71-1 [Last accessed: 22May 2026]."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313811"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920"},{"key":"e_1_3_2_38_1","unstructured":"37.U.S. Food and Drug Administration. Blenrep (belantamab mafodotin-blmf) prescribing information. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761440s000lbl.pdf [Last accessed: 3June 2026]."},{"key":"e_1_3_2_39_1","unstructured":"38.U.S. Food and Drug Administration. ELAHERE (mirvetuximab soravtansine-gynx) prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761310Origs005lbl.pdf [Last accessed: 3June 2026]."},{"key":"e_1_3_2_40_1","unstructured":"39.U.S. Food and Drug Administration. TIVDAK (tisotumab vedotin-tftv) prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761208s007lbl.pdf [Last accessed: 3June 2026]."},{"key":"e_1_3_2_41_1","unstructured":"40.U.S. Food and Drug Administration. DATROWAY (datopotamab deruxtecan-dlnk) prescribing information. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761464s000lbl.pdf [Last accessed: 3June 2026]."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00280-8"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom15070936"},{"key":"e_1_3_2_44_1","first-page":"4602","article-title":"Macropinocytosis inhibition mitigates antibody-drug conjugate (ADC) corneal toxicity in vitro","volume":"66","author":"Yan R","year":"2025","unstructured":"43.Yan R, , Lindgren ES, , Chan MF, et al. Macropinocytosis inhibition mitigates antibody-drug conjugate (ADC) corneal toxicity in vitro. Invest Ophthalmol Vis Sci 2025;66:4602.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-3745"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7871"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000391"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2017.02.008"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261475776","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261475776","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261475776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:52:06Z","timestamp":1786380726000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261475776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":47,"alternative-id":["10.1177\/10807683261475776"],"URL":"https:\/\/doi.org\/10.1177\/10807683261475776","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"10807683261475776"}}